Print pageHome » News: BMS' Tabora to Receive Award for Excellence in QbD
News: BMS' Tabora to Receive Award for Excellence in QbD
Scale-up Systems Limited
09/26/2011
The Pharmaceuticals division of AIChE has announced that Dr. Jose Tabora of Bristol Myers Squibb will receive the 2011 AIChE Award for Outstanding Contribution to Quality by Design (QbD) for Drug Substance. DynoChem Inc, the North American subsidiary of Scale-up Systems Limited, continues its sponsorship of the Award, worth $1500 and a commemorative plaque.
Dr. Tabora was nominated for his leadership role in application of advanced computational tools and approaches for data generation, exploration, visualization and analysis to support the Quality by Design framework and for his publications on QbD tools and techniques.
Dr. Joe Hannon, Managing Director of Scale-up Systems, who helped to coordinate the awards process, congratulated Dr Tabora, noting that "Jose has been instrumental in showing how to link tools such as statistical and first principles modeling to deliver QbD and we look forward to extending the reach of these tools for the benefit of the whole pharmaceutical community".
The QbD Topical Conference Program at the AIChE Annual Meeting, thanks to volunteer efforts of session chairs from industry, regulators and academia, features many high quality sessions on the scientific and practical aspects of QbD implementation. Full details are available at http://aiche.confex.com/aiche/2011/webprogram/TI.html and http://aiche.confex.com/aiche/2011/webprogram/Symposium1926.html. Online registration is available at: http://www.aiche.org/Conferences/AnnualMeeting/index.aspx.
A parallel prize for QbD for Drug Product, sponsored by Pfizer Inc, will be awarded to members of the Chantix/Champix Real Time Release team. 2011 also features a new third award, sponsored by Merck & Co, for Excellence in Integrated QbD Practice. All three QbD awards will be presented at a special session on Tuesday evening, October 18:
Further coverage of the awards is available at www.PharmaQbD.com.
About DynoChem
DynoChem is the world's leading process design, development and scale-up software for scientists and engineers working in the pharmaceutical industry.
About Scale-up Systems
Scale-up Systems supports companies in increasing productivity in R&D and Manufacturing by the adoption of appropriate technologies, enabling collaboration across traditional boundaries and embracing Quality by Design. The company has been operating since 1994 and subsidiaries include its North American distributor, DynoChem, Inc. and its Indian distributor, Scale-up Systems India Pvt. Ltd. For further information, please visit www.scale-up.com.
AIChE Pharma Open Forum
To connect with AIChE Pharma programming, join the AIChE Pharma Open Forum on LinkedIn.
More News:
-
05/17/2012
Study: US Clears Drugs Faster Than Europe, CanadaFrom WSJ.com
Researchers say the U.S. approved more new medicines in less time than Europe and Canada in the last decade, challenging long-standing criticisms that the Food and Drug Administration lags behind its peers in clearing important new drugs.
-
05/10/2012
Ex-Sanofi Chemist Sentenced To 18 Months For Trade Secrets TheftFrom WSJ.com
A 30-year-old former research chemist for pharmaceutical firm Sanofi was sentenced to 18 months in prison for stealing Sanofi trade secrets and making them available through another company, the U.S. Department of Justice said.
-
04/27/2012
Novo Nordisk Expanding U.S. Workforce 15 Percent
Most new positions are in sales and management, but manufacturing jobs will be added in Clayton, N.C.
-
04/26/2012
AstraZeneca’s Brennan to Retire; Lowth Named Interim CEOFrom Bloomberg.com
AstraZeneca Chief Executive Officer David Brennan will retire from his post, ending a six- year tenure after repeated failures in drug development left investors skeptical of the company’s earnings prospects.
-
04/19/2012
Congress Pushing to Allow Generic Drug Manufacturers to Make Label ChangesFrom Pharmalot
The U.S. Congress has introduced bills that would allow generic makers to make updates to labels as new safety and efficacy information becomes available.
- 04/18/2012 GSK Shifts to Unassigned Seating in RTP Offices
- 04/17/2012 Amgen CEO Comes Clean: I Was Arrogant and an Awful Listener
- 04/16/2012 Product News: Growth Direct Systems for Environmental Monitoring and Sterility
-
04/12/2012
J&J Fined $1.2 Billion in Drug CaseFrom NYTimes.com
A judge in Arkansas ordered Johnson & Johnson and a subsidiary to pay more than $1.2 billion in fines on Wednesday, a day after a jury found that the companies had minimized or concealed the dangers associated with an antipsychotic drug.
- 04/11/2012 Humira Set to Become World's Top-Selling Drug
- All news »
Get Connected Now!
- Featured White Papers
Sponsored Links
